News Articles | Pfizer Singapore

Biopharma Leaders Unite To Stand With Science

Pfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19

PFIZER INVESTS $120MIL IN BIOTECH INNOVATION

Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027

AGREEMENT REACHED WITH COVAX FOR ADVANCE PURCHASE OF COVID-19 VACCINE

RECENT PRESS RELEASES

05/08/2020 - LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer

05/08/2020 - Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate

31/07/2020 - Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate

28/07/2020 - Pfizer Reports Second-Quarter 2020 Results

27/07/2020 - Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study

22/07/2020 - Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

20/07/2020 - Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data

20/07/2020 - Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2

13/07/2020 - Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2

09/07/2020 - Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance

06/07/2020 - Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations across Asia Pacific

01/07/2020 - Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2

30/06/2020 - FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

30/06/2020 - European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

25/06/2020 - Pfizer Declares Third-Quarter 2020 Dividend